Antibiotic-loaded poly-ε-caprolactone and porous β-tricalcium phosphate composite for treating osteomyelitis

Takahiro Miyai, Atsuo Ito, Gaku Tamazawa, Tomonori Matsuno, Yu Sogo, Chiho Nakamura, Atsushi Yamazaki, Tazuko Satoh

    Research output: Contribution to journalArticle

    66 Citations (Scopus)

    Abstract

    A composite of poly-ε-caprolactone (PCL) loaded with gatifloxacine (GFLX), an antibiotic, and a β-tricalcium phosphate (βTCP) porous ceramic body was prepared by a solvent-free process in which no toxic solvent was used. GFLX mostly retained its bactericidal property after the processing. The composite of GFLX-loaded PCL and βTCP ceramic released GFLX for 4 weeks in Hanks' balanced solution, and had sustained bactericidal activity against Streptococcus milleri and Bacteroides fragilis for at least 1 week. The composite of the GFLX-loaded PCL and βTCP ceramic was implanted in an osteomyelitis lesion induced by S. milleri and B. fragilis in the rabbit mandible. The osteomyelitis lesion expanded in the mesial-distal direction when no composite was implanted or when the lesion was treated with debridement only. The composite of GFLX-loaded PCL and βTCP showed efficacy in controlling infection at the bone defect formed by debridement, and supported bone tissue reconstruction at the bone defect. Twelve and 50 weeks after the implantation, the inflammation even disappeared. New bone formation was observed on the surface of the composite after 4 weeks. After 50 weeks, ingrowth of bone tissues with vascular channels was observed along the PCL and βTCP interface, which indicated degradation of PCL and/or βTCP ceramic at the ceramic/polymer interface followed by replacement by bone tissues. The GFLX concentrations in the serum and soft tissues were very low. Therefore, the composite of GFLX-loaded PCL and βTCP ceramic would help arrest osteomyelitis when it is used in addition to intravenous antibiotic administration, and help new bone formation and osteoconduction.

    Original languageEnglish
    Pages (from-to)350-358
    Number of pages9
    JournalBiomaterials
    Volume29
    Issue number3
    DOIs
    Publication statusPublished - 2008 Jan

    Fingerprint

    Antibiotics
    Osteomyelitis
    Bone
    Phosphates
    Anti-Bacterial Agents
    Composite materials
    Bone and Bones
    Tissue
    Streptococcus milleri Group
    Bacteroides fragilis
    Debridement
    Osteogenesis
    Defects
    Bone Regeneration
    tricalcium phosphate
    gatifloxacin
    polycaprolactone
    Poisons
    Ceramics
    Mandible

    Keywords

    • Animal model
    • Antimicrobial
    • Calcium phosphate
    • Drug delivery
    • Osteoconduction
    • Polycaprolactone

    ASJC Scopus subject areas

    • Biotechnology
    • Bioengineering
    • Biomedical Engineering

    Cite this

    Antibiotic-loaded poly-ε-caprolactone and porous β-tricalcium phosphate composite for treating osteomyelitis. / Miyai, Takahiro; Ito, Atsuo; Tamazawa, Gaku; Matsuno, Tomonori; Sogo, Yu; Nakamura, Chiho; Yamazaki, Atsushi; Satoh, Tazuko.

    In: Biomaterials, Vol. 29, No. 3, 01.2008, p. 350-358.

    Research output: Contribution to journalArticle

    Miyai, Takahiro ; Ito, Atsuo ; Tamazawa, Gaku ; Matsuno, Tomonori ; Sogo, Yu ; Nakamura, Chiho ; Yamazaki, Atsushi ; Satoh, Tazuko. / Antibiotic-loaded poly-ε-caprolactone and porous β-tricalcium phosphate composite for treating osteomyelitis. In: Biomaterials. 2008 ; Vol. 29, No. 3. pp. 350-358.
    @article{a0bc5057217b424e83d18fdbc6b1d2d1,
    title = "Antibiotic-loaded poly-ε-caprolactone and porous β-tricalcium phosphate composite for treating osteomyelitis",
    abstract = "A composite of poly-ε-caprolactone (PCL) loaded with gatifloxacine (GFLX), an antibiotic, and a β-tricalcium phosphate (βTCP) porous ceramic body was prepared by a solvent-free process in which no toxic solvent was used. GFLX mostly retained its bactericidal property after the processing. The composite of GFLX-loaded PCL and βTCP ceramic released GFLX for 4 weeks in Hanks' balanced solution, and had sustained bactericidal activity against Streptococcus milleri and Bacteroides fragilis for at least 1 week. The composite of the GFLX-loaded PCL and βTCP ceramic was implanted in an osteomyelitis lesion induced by S. milleri and B. fragilis in the rabbit mandible. The osteomyelitis lesion expanded in the mesial-distal direction when no composite was implanted or when the lesion was treated with debridement only. The composite of GFLX-loaded PCL and βTCP showed efficacy in controlling infection at the bone defect formed by debridement, and supported bone tissue reconstruction at the bone defect. Twelve and 50 weeks after the implantation, the inflammation even disappeared. New bone formation was observed on the surface of the composite after 4 weeks. After 50 weeks, ingrowth of bone tissues with vascular channels was observed along the PCL and βTCP interface, which indicated degradation of PCL and/or βTCP ceramic at the ceramic/polymer interface followed by replacement by bone tissues. The GFLX concentrations in the serum and soft tissues were very low. Therefore, the composite of GFLX-loaded PCL and βTCP ceramic would help arrest osteomyelitis when it is used in addition to intravenous antibiotic administration, and help new bone formation and osteoconduction.",
    keywords = "Animal model, Antimicrobial, Calcium phosphate, Drug delivery, Osteoconduction, Polycaprolactone",
    author = "Takahiro Miyai and Atsuo Ito and Gaku Tamazawa and Tomonori Matsuno and Yu Sogo and Chiho Nakamura and Atsushi Yamazaki and Tazuko Satoh",
    year = "2008",
    month = "1",
    doi = "10.1016/j.biomaterials.2007.09.040",
    language = "English",
    volume = "29",
    pages = "350--358",
    journal = "Biomaterials",
    issn = "0142-9612",
    publisher = "Elsevier BV",
    number = "3",

    }

    TY - JOUR

    T1 - Antibiotic-loaded poly-ε-caprolactone and porous β-tricalcium phosphate composite for treating osteomyelitis

    AU - Miyai, Takahiro

    AU - Ito, Atsuo

    AU - Tamazawa, Gaku

    AU - Matsuno, Tomonori

    AU - Sogo, Yu

    AU - Nakamura, Chiho

    AU - Yamazaki, Atsushi

    AU - Satoh, Tazuko

    PY - 2008/1

    Y1 - 2008/1

    N2 - A composite of poly-ε-caprolactone (PCL) loaded with gatifloxacine (GFLX), an antibiotic, and a β-tricalcium phosphate (βTCP) porous ceramic body was prepared by a solvent-free process in which no toxic solvent was used. GFLX mostly retained its bactericidal property after the processing. The composite of GFLX-loaded PCL and βTCP ceramic released GFLX for 4 weeks in Hanks' balanced solution, and had sustained bactericidal activity against Streptococcus milleri and Bacteroides fragilis for at least 1 week. The composite of the GFLX-loaded PCL and βTCP ceramic was implanted in an osteomyelitis lesion induced by S. milleri and B. fragilis in the rabbit mandible. The osteomyelitis lesion expanded in the mesial-distal direction when no composite was implanted or when the lesion was treated with debridement only. The composite of GFLX-loaded PCL and βTCP showed efficacy in controlling infection at the bone defect formed by debridement, and supported bone tissue reconstruction at the bone defect. Twelve and 50 weeks after the implantation, the inflammation even disappeared. New bone formation was observed on the surface of the composite after 4 weeks. After 50 weeks, ingrowth of bone tissues with vascular channels was observed along the PCL and βTCP interface, which indicated degradation of PCL and/or βTCP ceramic at the ceramic/polymer interface followed by replacement by bone tissues. The GFLX concentrations in the serum and soft tissues were very low. Therefore, the composite of GFLX-loaded PCL and βTCP ceramic would help arrest osteomyelitis when it is used in addition to intravenous antibiotic administration, and help new bone formation and osteoconduction.

    AB - A composite of poly-ε-caprolactone (PCL) loaded with gatifloxacine (GFLX), an antibiotic, and a β-tricalcium phosphate (βTCP) porous ceramic body was prepared by a solvent-free process in which no toxic solvent was used. GFLX mostly retained its bactericidal property after the processing. The composite of GFLX-loaded PCL and βTCP ceramic released GFLX for 4 weeks in Hanks' balanced solution, and had sustained bactericidal activity against Streptococcus milleri and Bacteroides fragilis for at least 1 week. The composite of the GFLX-loaded PCL and βTCP ceramic was implanted in an osteomyelitis lesion induced by S. milleri and B. fragilis in the rabbit mandible. The osteomyelitis lesion expanded in the mesial-distal direction when no composite was implanted or when the lesion was treated with debridement only. The composite of GFLX-loaded PCL and βTCP showed efficacy in controlling infection at the bone defect formed by debridement, and supported bone tissue reconstruction at the bone defect. Twelve and 50 weeks after the implantation, the inflammation even disappeared. New bone formation was observed on the surface of the composite after 4 weeks. After 50 weeks, ingrowth of bone tissues with vascular channels was observed along the PCL and βTCP interface, which indicated degradation of PCL and/or βTCP ceramic at the ceramic/polymer interface followed by replacement by bone tissues. The GFLX concentrations in the serum and soft tissues were very low. Therefore, the composite of GFLX-loaded PCL and βTCP ceramic would help arrest osteomyelitis when it is used in addition to intravenous antibiotic administration, and help new bone formation and osteoconduction.

    KW - Animal model

    KW - Antimicrobial

    KW - Calcium phosphate

    KW - Drug delivery

    KW - Osteoconduction

    KW - Polycaprolactone

    UR - http://www.scopus.com/inward/record.url?scp=35848962289&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=35848962289&partnerID=8YFLogxK

    U2 - 10.1016/j.biomaterials.2007.09.040

    DO - 10.1016/j.biomaterials.2007.09.040

    M3 - Article

    C2 - 17977596

    AN - SCOPUS:35848962289

    VL - 29

    SP - 350

    EP - 358

    JO - Biomaterials

    JF - Biomaterials

    SN - 0142-9612

    IS - 3

    ER -